

Goa Carbon Limited



Registered & Corporate Office:

Dempo House, Campal, Panjim - Goa - 403 001., INDIA.
Tel.: +91 (0832) 2441300 Fax: +91 (0832) 2427192
E-mail: goacarbon@gmail.com Website: www.goacarbon.com
Corporate Identity Number - L23109GA1967PLC000076



Company Scrip Code / Symbol: 509567 / GOACARBON

ISIN Code: INE426D01013

Ref. No.: 2020\139

8th May 2020

The General Manager
Department of Corporate Services
BSE Limited, Thru' Listing Centre
25th Floor, P. J. Towers, Dalal Street,
Mumbai 400001

The Listing Department
National Stock Exchange of India Ltd., Thru' NEAPS
Exchange Plaza, Bandra Kurla Complex,
Bandra (East),
Mumbai 400051

Sub.: Copy of Notice to Shareholders published in newspapers for transfer of Equity Shares to IEPF Authority

Dear Sirs,

In accordance with Rule 6 of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 (as amended) and pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of the Notice published by the Company in the newspapers today i.e. 8th May 2020 for the attention of the Shareholders of the Company with respect to transfer of Equity Shares to the Investor Education and Protection Fund Authority.

This is for your information and record.

Yours faithfully,
For **Goa Carbon Limited**

Pravin Satardekar
Company Secretary
ACS 24380

Encl.: as above



Plants :

GOA : Tel.: 0832-2860363 to 68, 2860336, 2861052
Fax: 2860364 E-mail: head_works@goacarbon.com

PARADEEP : Tel: 07894462761 09238110372
E-mail: pcvpster@gmail.com

BILASPUR : Tel.: +91 (07752) 261220, 650720
Fax +91 (07752) 261115 E-mail: bsp@goacarbon.com

ISO 9001:2015

BUREAU VERITAS
Certification



ISO 14001:2015

BUREAU VERITAS
Certification



India looks to lure more than 1,000 US companies out of China

Govt is prioritising medical equipment suppliers, food processing units, textiles, leather and auto part makers

ARCHANA CHAUDHARY
New Delhi, May 7



India expects to win over US companies involved in healthcare products and devices

INDIA IS SEEKING to lure US businesses, including medical devices giant Abbott Laboratories, to relocate from China as President Donald Trump's administration steps up efforts to blame Beijing for its role in the coronavirus pandemic.

The government in April reached out to more than 1,000 companies in the US and through overseas missions to offer incentives for manufacturers seeking to move out of China, according to Indian officials who asked not to be identified, citing rules on speaking with the media. India is prioritising medical equipment suppliers, food processing units, textiles, leather and auto part makers among more than 550 products covered in the discus-

sions, they said.

Trump's move to blame China for its handling of the Covid-19 outbreak, which has killed more than a quarter-million people worldwide, is expected to worsen global trade ties as companies and governments move resources out of the world's second-largest economy to diversify supply chains. Japan has earmarked \$2.2 billion to help shift factories from its neighbour, while European Union members plan to cut dependence on Chinese suppliers.

For Prime Minister Narendra Modi, a surge in investment would help shore up an economy battered by an eight-

week nationwide lockdown to control the Covid-19 outbreak, and help him make up ground hitting a target to grow its manufacturing sector to 25% of gross domestic product by 2022 from 15%. The need to create employment is now even more urgent after the pandemic left 122 million people jobless and forced India to shut down all major cities.

It could also present India with a chance to finally push through long-stalled reforms on land, labour and taxes that have hindered investment for years. Modi's second term has been marred by nationwide protests and slow growth since his party scored a landslide election vic-

tory a year ago, presenting a risk for companies planning to move.

"There are opportunities for India to try to gain a place in global supply chains, but this will require serious investments in infrastructure and governance," said Paul Staniland, an associate professor at the University of Chicago who writes about India's politics and foreign policy. "India faces tough competition from elsewhere in South and Southeast Asia."

Officials have told companies that India is more economical in terms of securing land and affordable skilled labour than if they moved back to the US or Japan, even if overall costs are still higher than China. They have also offered an assurance that India will consider specific requests on changes to labour laws, which have proved a major stumbling block for companies, and said the government is considering a request from e-commerce companies to postpone a tax on digital transactions introduced in this year's budget.

India's trade ministry has sought detailed feedback from US companies on changes needed to make the country's tax and labour laws more favourable to companies, said one of the officials. Modi's gov-

ernment is working with states to ensure long term solutions, the official added, including developing land banks to ensure a quick start for units.

India expects to win over US companies involved in health-care products and devices, and is in talks with Medtronic and Abbott Laboratories on relocating their units to the country, an official said. Medtronic spokesman Ben Petok and Abbott spokeswoman Darcy Ross didn't immediately respond to emails seeking comment.

Both Medtronic and Abbott have a presence in India, which may make it easier for them to move their China supply chains to the country, according to an official. They're based out of financial center Mumbai and already work with large Indian hospital groups.

India's trade ministry spokesman didn't respond to an email seeking comment on the effort to lure US companies.

The push by Modi's government comes as India tries to regain lost ground after many companies chose countries like Vietnam over India as an alternative destination when Trump started his trade war with China.

— BLOOMBERG

Refunds for garment exporters: Govt clears ₹3k-cr pending claims

BANIKINKAR PATTANAYAK
New Delhi, May 6



TO EASE LIQUIDITY for garment and made-up exporters, the government has cleared long-pending claims worth roughly ₹3,000 crore since January under a so-called Rebate of State and Central Taxes & Levies (RoSCTL) scheme, trade sources told FE.

The revenue department has also asked the directorate general of foreign trade (DGFT) to release ₹464 crore against pending claims under another scheme, Remission of State Levies, which was replaced with the RoSCTL programme — meant for compensating them for various state as well as central government impost — on March 7, 2019. Benefits under the RoSL were stuck for more than a year, triggering protests from the cash-strapped exporters.

In an office memorandum dated April 30, reviewed by FE, the revenue department has said it has approved the release of the RoSL benefits, which will, however, be in the form of scrips, instead of cash. Ex-

porters will also be allowed to use the scrip for the payment of customs and central excise duties. Apparel Export Promotion Council chairman A Sakthivel welcomed the government's move and expected that the benefit comes at a time when the industry is going through a rough patch due to the Covid-19 outbreak.

The move comes at a time when the Covid-19 outbreak has already accentuated a slowdown in merchandise exports. Outbound shipments of garments shrank 4% year-on-year in FY20 to \$15.5 billion (even on a favourable base), aiding a decline in overall exports that contracted by close to 5% in FY20.

But the government has already scrapped benefits under

the Merchandise Exports from India Scheme (MEIS) for garments and made-up exporters retrospectively from March 7, 2019. However, to offer some relief to the exporters from the retrospective move, an earlier government order had said if the RoSCTL benefit between March 7 and December 31, 2019, was lower than the combined incentives under the MEIS and RoSL (which they were enjoying until the RoSCTL roll-out), the government would provide an "additional ad-hoc incentive" of up to 1% of FoB value of exported products, with a cap of ₹600 crore, for this period.

But, compounding exporters' woes, it had asked those who had availed of the MEIS benefits between March 7 and July 31, 2019 (after which MEIS benefits were blocked to them), to return the incentives, or the amount could be suitably adjusted against their future benefits. Exporters had said even with the extra incentive, the total benefit was lower by as much as two percentage points than what they used to get in March 2019

CSIR submits 53 genome sequences of coronavirus in Indians to global body

PRASHANT RANGNEKAR
New Delhi, May 7

AMIDST CONCERNS THAT coronavirus have undergone mutation and the new strain maybe more contagious, India's premier R&D organisation, CSIR, has submitted as many as 53 genome sequences of the virus to a global genome database, a move that may help in better understanding of the virus and developing a vaccine.


The Council for Scientific and Industrial Research (CSIR) is also planning to submit additional 450 genome sequence data of coronavirus by May 15, its director general Shekhar Mande told PTI. CSIR's Institute of Genomics and Integrative Biology (IGIB), Delhi, Centre for Cellular and Molecular Biology (CCMB), Hyderabad and Institute of Microbial Technology, Chandigarh are currently sequencing the genomes of the novel coronavirus, he said. Other CSIR institutes are also expected to join the process.

"We have so far submitted 53 genome sequences to the GISAID (Global Initiative on Sharing All Influenza Data). By May 15, we intend to submit additional 450 genome sequences," Mande said, adding all 53 have been sequenced by the scientists at the IGIB.

Genome sequencing is figuring out the order of DNA nucleotides. It helps in understanding how genes work together to direct the growth, development and maintenance of an organism.

IGIB director Anurag Agarwal said in case of coronavirus, sequencing will help understand the origins of the virus.

For instance, if a virus emerges from a particular



Govt to conduct randomised clinical trial of ashwagandha

THE GOVERNMENT WILL conduct a randomised controlled clinical trial to assess the efficacy of ayurvedic drug *ashwagandha* as a preventive intervention among healthcare professionals and high-risk Covid-19 population in comparison with hydroxychloroquine. This will be a joint initiative of the ministries of AYUSH, health, and science and technology through the Council of Scientific and Industrial Research (CSIR) with technical support from

the Indian Council of Medical Research (ICMR), Union Health Minister Harsh Vardhan said on Thursday.

Simultaneously, the efficacy of ayurvedic drugs *yashtimadhu*, combination of Guduchi and Pippali and a poly-herbal formulation (AYUSH-64) along with *ashwagandha* will also be evaluated as a prophylaxis and add on to standard care in mild to moderate COVID-19 patients, Secretary in the Ministry of AYUSH Vaidya Rajesh Kotecha said. — PTI

cluster, sequencing will make it easier to identify its origin later when it is found in some other part of the country or world. Plus, it will be helpful in making the vaccines and drugs for it, he added.

Earlier this week, a study by a US-based science laboratory has indicated that there is a new, highly-potent strain of coronavirus that has spread globally and is more contagious than the virus in early days of the Covid-19 pandemic. In the Indian context, Mande said the sequences submitted to the GISAID by

the CSIR deals with the coronavirus detected in Indians.

Launched in 2008, the GISAID, a public-private partnership between the German government and the nonprofit organization, promotes the rapid sharing of data from all influenza viruses and the coronavirus causing Covid-19.

This includes genetic sequence and related clinical and epidemiological data associated with human viruses, and geographical as well as species-specific data linked to avian and other animal viruses.

Ahmedabad under total lockdown to curb corona

FE BUREAU
Ahmedabad, May 7

THE GUJARAT GOVERNMENT on Wednesday imposed a complete lockdown in Ahmedabad for seven days, starting Thursday, to curb the spread of Covid-19.

Additional chief secretary Rajiv Gupta has been given the charge to tackle the situation in the commercial capital of Gujarat. According to Gupta, except milk and medicine shops, the entire city would remain closed for a week.

Fruit and vegetable vendors, provision stores, super markets and online delivery boys have reportedly been proved to be super spreaders of coronavirus in the city, and all such activities have been suspended till further review after a week, said a senior official, adding that except medical stores, services and milk shops, everything will remain closed.

Health teams have been ordered to screen super spreaders with immediate effect. Gupta and his team have decided to take control of nine private hospitals having cumulative capacity of over 1,000 beds. They are in the process of taking control of 3-star hotels to convert them into Covid-19 care centres to put people in quarantine. After 21 employees of Ahmedabad-based Cadila Pharmaceuticals were found to be corona positive, the administration acted quickly and

sanitised the entire campus of the company near Dholka. The authority also sanitised the Dholka urban area.

CENTRAL RAILWAY
CORRIGENDUM
It is hereby notified that the date of opening of the works published under tender notices of DRM (W) Office, Central Railway are postponed as shown below. **Sr. No. 1. Tender Notice No. & date & Sr. No. at which the work published: CR-DRM-W-BB-2020-19 dt. 17-04-2020 Sr.No.1. Published date of opening: 8.5.2020. Postponed to: 12.5.2020. Sr. No. 2. Tender Notice No. & date & Sr. No. at which the work published: CR-DRM-W-BB-2020-19 dt. 17-04-2020 Sr.No.3. Published date of opening: 12.5.2020. Postponed to: 22.5.2020. All other terms and conditions will remain same. 18/51**
Railway Helpline 139

"IMPORTANT"
Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

Tirupur garment cluster adopts steady approach, sees no labour shortage

R RAVICHANDRAN
Chennai, May 7

THE TIRUPUR READYMADE garments/knitwear cluster has begun operations in a slow and steady manner. Being in the Red Zone category, the export units as many as 1,100 are happy to have resumed their operations with local workforce.

The units have been getting increased enquiries from buyers from the United States, European Union, among other countries, for samples and accordingly the units begun sending samplings.

EXPRESS Careers
KAMALA EDUCATION SOCIETY'S PRATIBHA COLLEGE OF COMMERCE & COMPUTER STUDIES
Recognized by Govt. of Maharashtra & Affiliated to Savitribai Phule Pune University
REQUIRED PRINCIPAL
Applications are invited from eligible candidates for the post of **Principal** in Undergraduate College. **Post open to all.**
Qualification & Experience: As per UGC and Savitribai Phule Pune University norms.
For more information please visit www.kes.org.in/appointments
Apply within 7 days to:
The Secretary, Kamala Education Society, Block D-III, Plot No. 3, Behind Mehta Hospital, Off Mumbai Pune Road, Chinchwad Station, Pune 411019.
Dr. Deepak Shah, Secretary, Kamala Education Society

YES BANK
YES BANK LIMITED: Regd. & Corporate Office: YES BANK Tower, IFC 2, 15th Floor, Senapati Bapat Marg, Elphinstone (W), Mumbai 400 013, India. CIN: L65190MH2003PLC143249, Website: www.yesbank.in, Tel: +91 (22) 3366 9000 Fax: +91 (22) 2421 4500, Email: shareholders@yesbank.in

AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2020

| PARTICULARS (₹ in Lakhs) | FOR THE QUARTER ENDED 31.03.2020 (Audited) | FOR THE YEAR ENDED 31.03.2020 (Audited) | FOR THE QUARTER ENDED 31.03.2019 (Audited) |
|---|---|--|---|
| Total income from operations | 5,81,859 | 29,50,810 | 8,38,823 |
| Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items) | (4,76,593) | (29,24,091) | (2,33,831) |
| Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items) | 3,64,907 | (20,82,591) | (2,33,831) |
| Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items) | 2,62,861 | (16,41,802) | (1,50,664) |
| Paid up Equity Share Capital (Face Value of ₹ 2 each) | 2,51,009 | 2,51,009 | 46,301 |
| Reserves (excluding Revaluation Reserve as shown in the audited Balance Sheet of previous year) | 19,21,620 | 19,21,620 | 26,44,119 |
| Earnings Per Share (before and after extraordinary items) (Not Annualized) (Face Value of ₹ 2/- each) | | | |
| - Basic ₹ (before extraordinary items) | (8.30) | (77.57) | (6.51) |
| - Diluted ₹ (before extraordinary items) | (8.30) | (77.57) | (6.46) |
| - Basic ₹ (after extraordinary items) | 5.95 | (56.07) | (6.51) |
| - Diluted ₹ (after extraordinary items) | 5.95 | (56.06) | (6.46) |

Extra-ordinary item - AT1 write-back amounting to ₹ 841,500 lakhs

Notes
1. The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the Stock Exchange websites (www.bseindia.com) and (www.nseindia.com) and bank website www.yesbank.in
2. Information relating to Total Comprehensive Income and Other Comprehensive income are not furnished as Ind AS is not yet made applicable to banks

Place: Mumbai
Date: May 06, 2020

For YES BANK Limited
Prashant Kumar
Managing Director & CEO



गोवा कार्बन लिमिटेड



नोंदणीकृत कार्यालय : धेंपो हाउस, कांपाल, पणजी, गोवा ४०३००१
दूरध्वनी : (०८३२) २४४१३०० फॅक्स : (०८३२) २४२७१९२, संकेतस्थळ : www.goacarbon.com
संकेतस्थळ: www.investorrelations@goacarbon.com, सीआयएन : L२३१०९जीए१९६७मीएलसी००००७६

समभागधारकांना सूचना

(कंपनीचे इक्विटी शेअर इन्वेस्टर एज्युकेशन आणि प्रोटेक्शन फंड (आयईपीएफ) खात्यात ट्रान्स्फर करणे) ही सूचना कंपनी कायदा २०१३, 'द अॅक्ट' कलम १२४(६)च्या अनुषंगाने, इन्वेस्टर एज्युकेशन आणि प्रोटेक्शन फंड प्राधिकरण (अकाउंटिंग, ऑडिट, ट्रान्स्फर अँड रिफंड) नियम २०१६ (नियम) आणि त्यात वेळोवेळी झालेल्या बदलांच्या अनुषंगाने देण्यात येत आहे.

कायद्याच्या कलमाप्रमाणे सात वर्षांपर्यंत दावा न करण्यात आलेली लाभांशाची रक्कम इन्वेस्टर एज्युकेशन आणि प्रोटेक्शन फंड प्राधिकरण (आयईपीएफ) वर्ग करण्यात यावी.

सध्याच्या कठीण परिस्थितीत शक्य मार्गाने समभागधारकांशी संपर्क साधला आहे. कंपनीने जाहीर केलेला लाभांश ज्यावर कुणीही सात वर्षे दावा केला नाही आणि ज्यांचा लाभांश आयईपीएफमध्ये वर्गीकृत होणार आहे, अशा संबंधित सर्व समभागधारकांची यादी कंपनीच्या www.goacarbon.com या संकेतस्थळावर अपलोड करण्यात आली आहे.

संबंधित समभागधारकांकडून ०८ ऑगस्ट २०२०पर्यंत कोणतीही सूचना प्राप्त न झाल्यास, नियमाप्रमाणे वेळेत पूर्तता करण्यासाठी नियमांचे बंधन असल्यामुळे कंपनीला दावा न झालेले समभाग उपरोल्लेखित नियमांप्रमाणे आयईपीएफ सस्पेन्स खात्यामध्ये दिलेल्या कोणतीही सूचना न देता खालीलप्रमाणे वर्ग करण्यात येतील.

जर समजा समभाग :

- प्रत्यक्षात समभाग प्रमाणपत्र आहे : कंपनी त्यांना मूळ समभाग प्रमाणपत्राच्या बदल्यात समभाग प्रमाणपत्राची दुसरी प्रत जारी करणार आहे, ज्यायोगे त्यांना आयईपीएफ प्राधिकरण/सस्पेन्स खात्यात ट्रान्स्फर करण्यात येणारे संबंधित समभाग वर्ग करता येणे शक्य होईल. जे समभाग त्यांच्या नावावर असतील ते आपोआप निकालात काढले जातील.
- डीमॅट फॉर्ममध्ये आहेत : कंपनी डिपॉझिटरीला कॉर्पोरेट अॅक्शनच्या माध्यमातून कळवून समभाग आयईपीएफच्या डीमॅट खात्यात वर्ग केले जातील.

भागधारकांनी हेही घ्यानात घ्यावे की, हक्क न सांगितलेले/ न चुकते केलेले डिविडंट आणि आयईपीएफ प्राधिकरण खात्यात ट्रान्स्फर करण्यात येणारे संबंधित शेअर सोबतच त्यावर असलेल्या इतर लाभांसह जर असल्यास, भागधारकांना आयईपीएफच्या www.iepf.gov.in या संकेतस्थळावर उपलब्ध असलेल्या वेब फॉर्म आयईपीएफ-५ भरून व त्याची प्रत सही करून वेब फॉर्म आयईपीएफ-५मध्ये नमूद करण्यात आलेल्या दस्तऐवजांसहक कंपनीच्या नोंदणीकृत पत्त्यावर पाठवून पुन्हा दावा करू शकतात.

भागधारक आणि आयईपीएफ सस्पेन्स अकाउंटला ट्रान्स्फर करण्यात येणारे शेअर या विषयीचा तपशील कंपनीच्या www.goacarbon.com या संकेतस्थळावर उपलब्ध आहे. आणि कंपनीद्वारे त्यांच्या संकेतस्थळावर अपलोड केलेली माहिती हीच नियमांप्रमाणे आयईपीएफ सस्पेन्स खात्यामध्ये समभाग वर्ग करण्याची सूचना आहे. कृपया लक्षात घ्यावे की, हक्क न सांगितलेले/ न चुकते केलेले डिविडंट आणि आयईपीएफ प्राधिकरण खात्यात ट्रान्स्फर करण्यात आलेले संबंधित शेअर याबाबतीत कुठल्याही प्रकारे कंपनीला जबाबदार धरता येणार नाही.

भागधारकांना या विषयी कोणती शंका असल्यास त्यांनी कंपनीचे नोंदणीकृत ट्रान्स्फर एजंट लिन्क इनटाइम इंडिया प्रायव्हेट लिमिटेड, युमिट : गोवा कार्बन लिमिटेड, सी-१०१, २४७ पार्क, एल. बी. एस. मार्ग, विक्रोळी (पश्चिम), मुंबई ४०००८३; दूरध्वनी : +९१-२२-४९१९८६२७०; ईमेल : iepf.shares@linkintime.co.in

गोवा कार्बन लिमिटेड साठी

सही/-

प्रवीण सातार्डेकर

कंपनी सचिव

स्थळ : गोवा
दिनांक : ७ मे २०२०